Halozyme and Bristol Myers Squibb Secure European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE in Multiple Solid Tumors Halozyme Therapeutics celebrates a significant regulatory milestone as Bristol Myers Squibb gains European Commission approval for a new subcutaneous formulation of…
BeOne Medicines Officially Launches Following Redomiciliation to Switzerland, Ushering in a New Era of Global Oncology Leadership BeOne Medicines Ltd. formerly known as BeiGene, Ltd., has officially entered a transformative new chapter in its corporate journey with the announcement of…
BioNTech to Showcase Broad Advancements in Oncology Pipeline at 2025 ASCO Annual Meeting BioNTech ,a global biotechnology company known for pioneering mRNA-based technologies, announced that it will present significant clinical trial data from its diversified oncology pipeline at the 2025…
Pharma Doubles Down on R&D Amid Global Headwinds, Eyes Nearly $340 Billion in Investment by 2030 Despite formidable political and economic challenges ranging from inflation and rising operational costs to geopolitical instability and regulatory pressures, the global pharmaceutical industry continued…
Takeda and Nature Open Applications for 2026 Innovators in Science Award to Celebrate Emerging Scientific Talent Takeda Pharmaceutical Company Limited has officially opened the application window for its prestigious Innovators in Science Award for the 2026 cycle. This distinguished global…
AstraZeneca’s Imfinzi Gains CHMP Backing as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer in the EU AstraZeneca has announced a significant regulatory milestone for its cancer immunotherapy, Imfinzi (durvalumab), with the drug receiving a positive recommendation from the Committee for…
AbbVie Highlights Expanding Oncology Pipeline at ASCO 2025 with New Data Across Challenging Solid Tumors and Blood Cancers AbbVie has announced a significant presence at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30…
Eli Lilly to Acquire SiteOne Therapeutics in $1 Billion Deal to Advance Non-Opioid Pain Therapy In a strategic move aimed at strengthening its neuroscience and pain management portfolio, Eli Lilly and Company (NYSE: LLY) announced on May 28, 2025, that…
Lupin and SteinCares Forge Strategic License and Supply Agreement to Commercialize Ranibizumab Biosimilar Across Latin America Global pharmaceutical leader Lupin Limited (Lupin) has officially announced the signing of a significant license and supply agreement with SteinCares, a prominent specialty healthcare…
Partnering for Progress: How Astellas and the Pompe Disease Community Are Shaping the Future Together Pompe disease is a rare, inherited, and progressively debilitating disorder that profoundly affects the lives of those diagnosed with it, as well as their families…
Practice-Changing Data, Innovative Modalities, and Global Impact Headline ASCO 2025 The oncology community is converging in Chicago this week for the highly anticipated 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), with excitement mounting over groundbreaking research…
U.S. Vaccine Innovation at Risk: How Four Biotechs Are Being Squeezed by Shifting Policies, Funding Cuts, and Regulatory Changes As the World Health Organization (WHO) sets a new course for global pandemic preparedness, efforts to develop next-generation COVID-19 vaccines in…
